We present an original application of competitive polymerase chain reaction (PCR) for measuring oncogene amplification in DNA from human tumors by simultaneous PCR amplification of genomic DNA with fixed amounts of an internal standard (competitor DNA). Competitors share the same sequence as the target genes but contain an additional 15-to 20-base-pair insert, which allows resolution of the amplified products after polyacrylamide gel electrophoresis and ethidium bromide staining. The gene copy number is derived from the ratio between the intensities of the bands corresponding to the amplified products. Using this procedure, we measured c-erbB-2 amplification in breast and bladder carcinomas in both fresh tumor tissues and paraffin-embedded tissue samples and assessed the precision, sensitivity, and accuracy of the (18, 20, (23) (24) (25) . We present here an original application of competitive PCR for measuring c-erbB-2 oncogene amplification. The method is based on absolute quantification of the number of gene copies of -globun (chosen as the single-copy reference gene) and c-erbB-2 genes in DNA extracted from human solid tumors, both fresh and paraffin-embedded tissues.
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Protooncogene amplification has been consistently observed in human tumors; for example, N-myc is amplified in neuroblastoma (1) and small-cell lung carcinoma (2), epidermal growth factor receptor gene in glioblastoma (3) , and int-2 and c-myc in breast cancer (4, 5) . Amplification of c-erbB-2 (HER2/neu), a protooncogene that encodes a 185-kDa transmembrane glycoprotein with putative growth factor receptor activity (6, 7) , has been reported in several human tumors, including neoplasms of the salivary gland (8), stomach and kidney (9) , bladder (10, 11), and breast and ovary (12) . Although a direct correlation between gene amplification and the pathogenetic mechanisms of tumorigenesis is not clear, in several cases the detection of gene amplification can serve as a genetic marker for prognosis. In breast and ovarian carcinoma, a direct correlation between amplification and c]inical outcome has been reported (12-14). In bladder transitional cell carcinoma, c-erbB-2 amplification has been considered rare by Wood et al. (18, 20, (23) (24) (25) . We present here an original application of competitive PCR for measuring c-erbB-2 oncogene amplification. The method is based on absolute quantification of the number of gene copies of -globun (chosen as the single-copy reference gene) and c-erbB-2 genes in DNA extracted from human solid tumors, both fresh and paraffin-embedded tissues.
Materials and Methods
Tumor Tissues and DNA Preparation 
We quantified these amplified fragments exactly by including 1 L of [32PIdCTP (3000 kCi/mol; Amersham, Amity-PG, Milan, Italy) in the reaction mixture and evaluating the specific activity of the products as previously described (26). We expressed competitor concentrations as number of molecules per microliter.
The primers were synthesized by the ICGEB Oligonucleotide Synthesis Service with an Applied Biosystem (Foster City, CA) AB 394-B synthesizer.
PCR Conditions
For PCR amplification we used a 480 Thermal Cycler from Perkin-Elmer Cetus (Norwalk, CT). Mononucleotides dATP, dCTP, dGTP, and dTTP were from Boehringer Mannheim 
Image Analysis
We measured the intensity of the two bands corresponding to genomic and competitor amplification products with a charge-coupled device (CCD) video camera (C3077/-01) from Hamamatsu Photonics (Hamamatsu City, Japan) connected with a video frame grabber (M4476; Hamamatsu).
The video frame grabber is a plug-in board used in a Macintosh Ilsi computer (Apple, Cupertino, CA 
Assay Procedure
The assay procedure for c-erbB-2 amplification in clinical samples was as follows (see Fig. 1 competitor/genomic intensity ratio
We utilized the sample in which the competitor/genomic intensity ratio (CIG) was closest to equivalence (ratio = 1), as shown in Fig. 1 (panel A, three lanes) . We subsequently coamplifled an aliquot of sample DNA corresponding to 30 x iO genomic equivalents with three dilutions of c-erbB-2 competitor ( as shown in Fig. 1 (panel B) . We calculated the final result from the sample in which the competitor/genomic ratio was closest to equivalence.
Precautions were taken to avoid carryover of amplification products, including physical separation of preand post-PCR procedures, ultraviolet irradiation of nondisposable devices, use of aerosol-resistant tips (Continental Laboratory Products, San Diego, CA), and assembling of master mix solutions to reduce manipulation of samples. We included several negative controls in each PCR experiment to ensure absence of contaminants, and also included amplified and nonamplified controls.
Results
Assay Evaluation
Linearity.
With competitive PCR, because of the disparity in size between genomic DNA and the synthetic competitor, one must verify equffibrium conditions with respect to the probe by demonstrating linearity of competitor/genomic ratios over a range of DNA concentrations (24). For this reason we performed two experiments to verify the dynamic range of competitive PCR: In the first one, we probed a constant amount of placental DNA (30 x iO genomic equivalents) with increasing amounts of c-erbB-2 competitor (from 4 x iO to 256 x iO molecules) in the presence of specific primers. After 40 cycles, competitor/genomic ratios (y) were measured and plotted against the number of competitor molecules added to each sample (x). We obtained a linear correlation (y = 0.052x -0.342, r = 0.996) in the range of 8 x iO to 256 x i03 molecules of added competitor. In a second experiment, we probed a constant amount of c-erbB-2 competitor (30 x iO molecules) with increasing amounts of genomic DNA (from 3.8 x iO to 240 x iO genomic equivalents) and processed this as in the first experiment.
In this case we observed a linear response for 7.5 x iO to 120 x iO molecules of competitor (y = 0.048x -0.441, r = 0.982). The wide range of linearity indicates that equilibrium conditions apply, Table 1 .
In another experiment, we mixed decreasing amounts of genomic DNA (from 30 x i0 to 0 genomic equivalents) extracted from the SKBR-3 cell line with increasing amounts of placental DNA (0 to 30 x iO genomic equivalents) and applied competitive PCR. This experiment tested the ability of competitive PCR to discrimi- Fig. 2 and are plotted against the expected values.
We determined the sensitivity of the assay in eight experiments with placental DNA (mean ± SD = 0.97 ± 0.04-fold amplification).
The value 3 SD above the unamplified point on the linear calibration curve indicates a theoretical detection limit of -1.2-fold amplification (Fig. 2) .
Reproducibility.
We calculated the CV of competitive PCR by replicate analysis of a sample. Whereas the efficiency of PCR was highly variable, as indicated by Fig. 3) .
RECONSTITUTEDSAMPLES
Studies with Cancer Cells c-erbB-2 amplification
in fresh and paraffin-embedded breast tumors. We determined the amplification of the c-erbB-2 oncogene in 22 unselected breast carcinoma patients. We found oncogene amplification in 7 patients (32%) and, although the number of cases is small, we observed an increased percentage of c-erbB-2 amplification in node-positive cases (38%), in estrogen receptornegative tumors (40%), and in progesterone receptornegative tumors (50%)-in agreement with previous reports (33).
We also applied competitive PCR to the measurement of c-erbB-2 amplification in 11 breast tumors in which DNA was extracted from both fresh tissue and from the corresponding specimen prepared for routine histopathological procedures. These formalin-fixed, paraffin-embedded samples were randomly chosen among tissues that had been archived 6-16 months before DNA extraction. Although DNA extracted from paraffin blocks was degraded to a variable extent, the number of samples showing amplification and the degree of c-erbB-2 amplification found in fixed specimens corresponded closely to those obtained with fresh tissues (Table 2) . We also saw close correspondence with a fixed tumor sample having highly degraded DNA because of long exposure to buffered formalin (Fig. 4) .
c-erbB-2 amplification
in human bladder carcinomas. Table 3 
Discussion
The use of basic molecular biology techniques in clinical laboratories requires not only a progressive simpli- The application of competitive PCR described here is a powerful and rapid method. It does not require the digestion of DNA with restriction enzymes, transfer of DNA to solid membranes, or isotopic hybridization, all of which can introduce variability in the traditional Southern blot procedure. The competitive PCR method allows an accurate quantification of gene copy number through use of an internal standard, i.e., a DNA competitor with a different length from the target (15-20 bp insert) but sharing the same primer recognition sites. Until now, the preparation of competitor templates was the major problem of competitive PCR, but a rapid and simple method for competitor preparation by overlap extension has recently been described (24). The precision of the present assay is also enhanced by the accurate measurement of the intensity of the bands corresponding to the PCR-amplified products, by using image analysis of fluorescence of ethidium bromidestained DNA with a CCD camera and specific software (25) .
We have demonstrated that one can obtain a dosedependent linear response by using a constant amount of genomic DNA with increasing concentrations of competitor, as well as the opposite (fixed competitor and increasing genomic DNA). These results indicate that the two DNA species are equivalent in relative efficiency of amplification.
This fact makes the assay adaptable to different conditions, for instance, by decreasing the genomic DNA concentration to reach equivalence with added competitor molecules when the value of oncogene amplification could not be determined by simply increasing the number of competitor molecules.
We have also given a preliminary evaluation of the proposed method for accuracy, precision, and sensitivity, using the same criteria applied to any new reference laboratory assay procedure. Although a complete evaluation of the analytical parameters of our PCR assay requires more in-depth studies, our results represent the first attempt to make competitive PCR a more quantitative tool in the clinical laboratory. The theoretical detection limit of the assay (1.2-fold) was more than sufficient to detect a biologically relevant twofold amplification.
We showed that the proposed method can be successfully applied to the measurement of oncogene ainplification even in previously fixed tissues, as clearly demonstrated by the results obtained with DNA extracted from the fresh tissue and from the corresponding paraffin-embedded preparation for routine histopathological examination.
This makes this assay suitable for retrospective studies.
Applying this procedure to 22 unselected primary breast carcinomas detected an increased number of c-erbB-2 gene copies in 7 cases (31.8%), with the amplification ranging from two-to eightfold. Amplification appears more frequent in node-positive patients and in estrogen receptor-negative and progesterone receptornegative tumors. Although the number of tumors investigated is small, the percentage of amplified samples is in the same range observed by others using different methodologies (33 In conclusion, competitive PCR is a simple, reliable, and accurate method for evaluating the c-erbB-2 amplification in DNA extracted from fresh or fixed tumor tissues. The method could potentially extend gene amplification analysis to routine use in the laboratory.
